Ladasten [Bromantane]

The product has been discontinued in 2017 and has not available since. We suggest to try out some of the similar adaptogens: Bemitil, Mildronate, Actovegin, Pantocrin  and Vasobral.

Ladasten (Bromantane) is a nootropic drug with anxiolytic and stimulating action.

Bromantane was developed in the 1970s by Zakusov Institute of Pharmacology (USSR) as a performance enhancer for use in military medicine and in the sport. It was popular among professional athletes in Russia before 1996 when Bromantane was added to doping list. Even after the ban, some Russian athletes continued to use it.

Currently, Ladasten marketed in Russia as an anti-asthenic drug, which means it is intended to treat asthenia. Asthenia is a term often used in Russian medicine which means lack of energy, lethargy, low motivation and chronic fatigue.

The pharmacological effects of Bromantane mediated mostly by its effect on the dopaminergic system. The drug does not bind to any specific receptors. It works by mediating the expression of 16 various genes which affects the nervous system. Bromantane possesses dopaminergic activity by stimulating the synthesis of tyrosine hydroxylase and DOPA-decarboxylase in striatum and hypothalamus, thus increasing dopamine levels without the risk of dopamine depletion.

Anxiolytic effect of Bromantane is believed to be mediated by reducing the expression of GABA transporter which increases the amount of GABA in the synaptic cleft.

Although Ladasten may have less pronounced stimulating action compared to typical stimulants such as amphetamines, it has considerable advantages over them:

• Bromantane have little to no addictive potential
• It helps to relieve anxiety rather than causing it
• Ladasten does not deplete the nervous system